Treatment of hospital-acquired pneumonia – Authors' Reply

Michael Niederman and colleagues raise concerns regarding our multicentre effort to implement American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) guidelines for treatment of health-care-associated, hospital-acquired, and ventilator-associated pneumonias.1 Specifically,...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2011-10, Vol.11 (10), p.731-732
Main Authors: Kett, Daniel H, Quartin, Andrew A, Mangino, Julie E, Zervos, Marcus J, Ramirez, Julio A
Format: Article
Language:English
Subjects:
Antibiotics
Health risks
Infectious Disease
Infectious diseases
Mortality
Mortality risk
Multidrug resistant organisms
Pathogens
Pneumonia
Pseudomonas
Staphylococcus aureus
Staphylococcus infections
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Michael Niederman and colleagues raise concerns regarding our multicentre effort to implement American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) guidelines for treatment of health-care-associated, hospital-acquired, and ventilator-associated pneumonias.1 Specifically, in patients at risk for multidrug-resistant pathogens, we reported that empirical antibiotic therapy conforming to guidelines was associated with increased mortality unexplained by patients' acuity or chronic conditions. [...]among all empirically treated patients, the point estimate for mortality risk was higher with dual Gram-negative therapy than with non-compliant therapy. IMPACT-HAP's results argue for future studies addressing if and when dual Gram-negative therapy should be prescribed for patients with pneumonia patients at risk of multidrug-resistant pathogens.
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(11)70265-1